Company: HURA
Filing Date: 2025-11-03
Form Type: S-3
Source: 0001193125-25-262843
Chunk: 1

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-11-03
Form: S-3
Chunk 1
---
 upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐ If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-acceleratedfiler, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2of the Exchange Act.

| Large accelerated filer |     | ☐ |     | Accelerated filer         |     | ☐ |
| Non-accelerated filer   |     | ☒ |     | Smaller reporting company |     | ☒ |
|                         |     |   |     | Emerging growth company   |     | ☐ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐ This registration statement shall hereafter become effective in accordance with the provisions of Section 8(a) of the Securities Act of 1933.

EXPLANATORY NOTE This Registration Statement contains a prospectus and a prospectus supplement, including:

| • |     | a base prospectus, which covers (i) the offering, issuance, and sale by us from time to time in one or more                                                                                                                                       
 offerings of up to $250,000,000 in the aggregate of debt securities, common stock, preferred stock, warrants, subscription rights, units, and/or purchase contracts, and (ii) the offering and sale by the selling stockholders identified in the 
 “Selling Stockholders” section of this prospectus from time to time of up to 9,321,545 shares of our common stock, par value $0.001 per share (“Common Stock”); and                                                                               |

| • |     | a prospectus supplement, or the ATM prospectus supplement, covering the offering, issuance and sale by us from                                                                   
 time to time of up to a maximum aggregate offering price of $50,000,000 of our Common Stock that may be issued